Diseases [C] » Immune System Diseases [C20] » Immunologic Deficiency Syndromes
Description
Syndromes in which there is a deficiency or defect in the mechanisms of immunity, either cellular or humoral. MeSH
Hierarchy View
Subtype Terms (8)
Agammaglobulinemia
29 drugs (27 approved, 2 experimental)
Common Variable Immunodeficiency
33 drugs (26 approved, 7 experimental)
HIV Infections
1062 drugs (452 approved, 610 experimental)
Lymphopenia
7 drugs (4 approved, 3 experimental)
Phagocyte Bactericidal Dysfunction
Primary Immunodeficiency Diseases
81 drugs (43 approved, 38 experimental)
Phase 3 Indicated Drugs (4)
Organization Involved with Phase 4 Indications (82)
Bill and Melinda Gates Foundation
California HIV/AIDS Research Program
Canadian AIDS Treatment Information Exchange
Community Research Initiative of New England
Instituto Mexicano del Seguro Social
Instituto Nacional de Ciencias Medicas y Nutricion
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Instituto Nacional de Enfermedades Respiratorias
Instituto Nacional de la Nutrición Salvador Zubiran
Laboratorios Nacionales de Biológicos y Reactrivos
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute on Drug Abuse (NIDA)
National Institutes of Health (NIH)
National University of Ireland
NHS Health Technology Assessment Programme
State University of New York, Buffalo
St. Vincent's Hospital-Manhattan
Organization Involved with Phase 3 Indications (87)
1st Allergy & Clinical Research Center
Allergy Associates of the Palm Beaches, North Palm Beach, FL
Allergy, Asthma and Immunology Clinic PA
Allergy, Asthma & Immunology Assoc., Omaha, NE
All India Institute of Medical Sciences
Asthma and Allergy Center, Papillion, NE
Case Western Reserve University
Egyesitett Szent Istvan es Szent Laszlo Korhaz, Budapest, Hungary
European and Developing Countries Clinical Trials Partnership (EDCTP)
First Allergy and Clinical Research Center, Engelwood, CO
Icahn School of Medicine at Mount Sinai
Maternity and Children Hospital, Makkah
Maternity and Children hospital,Mecca, Saudi Arabia
National Cancer Institute (NCI)
National Heart, Lung, and Blood Institute (NHLBI)
Omrix Biopharmaceuticals, Inc.
Pediatric Allergy/Immunology Associates, Dallas, TX
RojanPharma Pharmaceutical Company
Organization Involved with Phase 2 Indications (54)
AUTOMATIC SUBDERMAL INJECTOR SYSTEM, INC
Blood and Marrow Transplant Clinical Trials Network
California Institute for Medical Research
California Institute for Regenerative Medicine
Children's Hospital Los Angeles
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Hoosier Cancer Research Network
Institut National de la Santé Et de la Recherche Médicale, France
International Partnership for Microbicides
International Partnership for Microbicides, Inc.
National Center for Complementary and Integrative Health (NCCIH)
National Center for Research Resources (NCRR)
National Institute of Dental and Craniofacial Research (NIDCR)
Organization Involved with Other Experimental Indications (30)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
